Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary Endpoint
Go back to Atea Pharmaceuticals Inc. (AVIR) Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Did Not Meet the Primary Endpoint| (NASDAQ: AVIR) | Delayed: 5.64 +0.21 (3.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.43 | 52 Week High | $2.00 | |||
| Open | $5.46 | 52 Week Low | $1.15 | |||
| Day High | $5.66 | P/E | N/A | |||
| Day Low | $5.38 | EPS | $0.00 | |||
| Volume | 237,550 | |||||
